Skip to main content
SpringerLink
Log in

Overactive Bladder: Pharmacologic Therapy

  • Chapter
Pelvic Floor Dysfunction

Summary

Multiple effective agents are available orally, transdermally, and intravesically for the treatment of OAB. Most patients will respond to either of the available agents. In those patients with a greater degree of complexity, or a negative quality-of-life impact, we prefer to use an oxybutynin-based agent, either orally or transdermally, because the circulating level can be individualized via a combination of doses and routes, realizing that expected dry mouth severity may limit patient compliance, although tolterodine may be preferable in the elderly poly-pharmacy patient. The future of OAB therapy looks promising as new agents increase the available treatment options for patients with OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168(2):580–586.

    Article  PubMed  CAS  Google Scholar 

  2. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995–2000.

    Article  PubMed  CAS  Google Scholar 

  3. Burgio KL, Locher JL, Goode PS, et al. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000;48:370–374.

    PubMed  CAS  Google Scholar 

  4. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6(3):243–262.

    Article  PubMed  CAS  Google Scholar 

  5. Thuroff JW, Chartier-Kastler E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998;(16suppl 1):S48–S61.

    Article  PubMed  CAS  Google Scholar 

  6. Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. Journal of Urology 2002;168:1897–1913.

    Article  PubMed  CAS  Google Scholar 

  7. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161(6):1809–1812.

    Article  PubMed  CAS  Google Scholar 

  8. Larsson G, Hallen B, Nilvebrant L, Tolterodine in the treatment of overactive bladder: an analysis of the pooled phase II efficacy and safety data. Urology 1999;53(5):990–998.

    Article  PubMed  CAS  Google Scholar 

  9. Van Kerrebroeck P, Amarenco G, Thuroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998;17(5):499–512.

    Article  PubMed  Google Scholar 

  10. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998;81(1):42–48.

    PubMed  CAS  Google Scholar 

  11. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(6A suppl):90–96; discussion 97–99.

    Article  PubMed  CAS  Google Scholar 

  12. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, on behalf of the Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57(3):414–421.

    Article  PubMed  Google Scholar 

  13. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Hosp Res Opin 2002;18(4):177–184.

    Article  CAS  Google Scholar 

  14. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687–695.

    PubMed  CAS  Google Scholar 

  15. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways that we treat the overactive bladder. J Urol 1999;162:3.

    Article  PubMed  CAS  Google Scholar 

  16. Schurch B, Stöhrer M, Kramer G, et al. Botulinum: a toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692.

    Article  PubMed  CAS  Google Scholar 

  17. Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of Trospium chloride in patient with detrusor instabiligy: a placebo-controlled, randomized, bouble blind, multicentre clinical trial. BJU Int 2000;85:659–664.

    Article  PubMed  CAS  Google Scholar 

  18. Hofner K, Oelke M, Machtens S, Grunewald V. Trospium chloride: an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001;19:336–343.

    Article  PubMed  CAS  Google Scholar 

  19. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76(4):358–363.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Urogynecology and Reconstructive Pelvic Surgery, Department of Gynecology, Cleveland Clinic Florida, Weston, FL, USA

    Daniel H. Biller MD & G. Willy Davila MD

Authors
  1. Daniel H. Biller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Willy Davila MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Gynecology, Cleveland Clinic Florida, Weston, FL, USA

    G. Willy Davila MD (Chairman, Head and Affiliate Associate Professor) (Chairman, Head and Affiliate Associate Professor)

  2. Section of Urogynecology and Reconstructive Pelvic Surgery, Cleveland Clinic Florida, Weston, FL, USA

    G. Willy Davila MD (Chairman, Head and Affiliate Associate Professor) (Chairman, Head and Affiliate Associate Professor)

  3. University of South Florida, USA

    G. Willy Davila MD (Chairman, Head and Affiliate Associate Professor) (Chairman, Head and Affiliate Associate Professor)

  4. Section of Voiding Dysfunction, Female Urology and Reconstruction, NOVA Southeastern University, Ohio State University and University of South Florida, Cleveland Clinic Florida, Weston, FL, USA

    Gamal M. Ghoniem MD, FACS (Head and Clinical Professor of Surgery/Urology) (Head and Clinical Professor of Surgery/Urology)

  5. NOVA Southeastern University, Ohio State University and University of South Florida, Cleveland Clinic Florida, Weston, FL, USA

    Gamal M. Ghoniem MD, FACS (Head and Clinical Professor of Surgery/Urology) (Head and Clinical Professor of Surgery/Urology)

  6. 21st Century Oncology Chair in Colorectal Surgery, Cleveland Clinic Hospital, USA

    Steven D. Wexner MD, FACS, FRCS, FRCSED (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor) (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor)

  7. Department of Colorectal Surgery, Cleveland Clinic Florida, USA

    Steven D. Wexner MD, FACS, FRCS, FRCSED (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor) (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor)

  8. Ohio State University Health Sciences Center at Cleveland Clinic Foundation, USA

    Steven D. Wexner MD, FACS, FRCS, FRCSED (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor) (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor)

  9. University of South Florida College of Medicine, USA

    Steven D. Wexner MD, FACS, FRCS, FRCSED (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor) (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor)

  10. Charles E. Schmidt College at Florida Atlantic University, USA

    Steven D. Wexner MD, FACS, FRCS, FRCSED (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor) (Chief of Staff, Chairman, Professor of Surgery, Clinical Professor of Surgery and Research Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Biller, D.H., Davila, G.W. (2006). Overactive Bladder: Pharmacologic Therapy. In: Davila, G.W., Ghoniem, G.M., Wexner, S.D. (eds) Pelvic Floor Dysfunction. Springer, London. https://doi.org/10.1007/1-84628-010-9_27

Download citation

  • DOI: https://doi.org/10.1007/1-84628-010-9_27

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-730-8

  • Online ISBN: 978-1-84628-010-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation